Biotechnology
Biogen's tau-targeting drug BIIB080 demonstrates a 26% slowing of cognitive decline, matching approved Alzheimer's therapies and potentially validating an entirely new treatment category for the disease.
Biotechnology
A first-in-human study from Northwell Health's Feinstein Institutes shows that a wearable ear device can activate the vagus nerve to accelerate blood clotting, opening a new frontier in bioelectronic medicine for hemorrhage control.
Biotechnology
GSK and Hansoh's ris-rez became the first B7-H3-targeted ADC to demonstrate an overall survival benefit in a Phase 3 trial. Here is what the ARTEMIS-008 result means for small-cell lung cancer patients, the ADC field, and GSK's oncology ambitions.
Pharmaceuticals
AstraZeneca and Ionis's eplontersen failed the CARDIO-TTRansform Phase 3 trial in ATTR-CM. The result reveals a deeper challenge: what happens when the standard of care evolves faster than the trial designed to test against it.
Biotechnology
The FDA approved Trutakna (atacicept) for IgA nephropathy on July 7, 2026, making it the first BAFF/APRIL dual inhibitor cleared for the disease. Here is what the approval means for patients, the competitive landscape, and the science of kidney disease.
Biotechnology
The FDA's expansion of Casgevy to children as young as 2 years old marks a milestone for CRISPR gene therapy, but significant access barriers remain a critical challenge for families.
Biotechnology
For five years, the KRAS G12C inhibitor market in lung cancer has been a story of scientific triumph and commercial disappointment. Amgen's Lumakras and Bristol Myers Squibb's Krazati were genuine breakthroughs when they launched in 2021 and 2022, respectively. They proved that KRAS, long considered undruggable,
Biotechnology
On July 29, an FDA advisory committee will evaluate deramiocel, Capricor's allogeneic cell therapy for Duchenne muscular dystrophy cardiomyopathy. If approved, it would be the first cell-based therapy targeting DMD cardiac dysfunction.
Biotechnology
Anthropic's announcement of Claude Science and its internal drug discovery program signals a major shift in how AI companies are approaching the life sciences—and what it means for pharmaceutical companies.
Biotechnology
Abivax's obefazimod showed impressive efficacy for ulcerative colitis but triggered investor panic over cancer signals. The June 29 data clarified the picture, revealing cancer rates consistent with disease background. Here's what the science actually shows.
Biotechnology
Ipsen's $1.75 billion acquisition of Kartos Therapeutics brings navtemadlin, a novel MDM2 inhibitor, to myelofibrosis patients who have failed ruxolitinib. The drug targets a complementary pathway with promising Phase 1b/2 data showing disease modification signals.
Biotechnology
Viridian Therapeutics' Lumvoa becomes the second FDA-approved treatment for thyroid eye disease, offering new hope for patients with both active and chronic TED.